[go: up one dir, main page]

SV2001000020A - Derivados de quinolina-2-uno substituido de heteroarilo util como agente anti-canceroso ref.pc10198/82888/bb - Google Patents

Derivados de quinolina-2-uno substituido de heteroarilo util como agente anti-canceroso ref.pc10198/82888/bb

Info

Publication number
SV2001000020A
SV2001000020A SV2000000020A SV2000000020A SV2001000020A SV 2001000020 A SV2001000020 A SV 2001000020A SV 2000000020 A SV2000000020 A SV 2000000020A SV 2000000020 A SV2000000020 A SV 2000000020A SV 2001000020 A SV2001000020 A SV 2001000020A
Authority
SV
El Salvador
Prior art keywords
quinoline
derivatives
substituted
compounds
formula
Prior art date
Application number
SV2000000020A
Other languages
English (en)
Inventor
Yang Beingwei Vera
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2001000020A publication Critical patent/SV2001000020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LOS COMPUESTOS DE FORMULA 1, VER FORMULA, Y A LAS SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE R1, R2, R3, R4, R5, R6, R7,R8, R9, Y Z SON COMO SE HA DEFINIDO EN LA PRESENTE. LA INVENCION TAMBIEN SE REFIERE A LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LOS COMPUESTOS DE FORMULA 1 Y A LOS PROCEDIMIENTOS DE INHIBICION DEL CRECIMIENTO CELULAR ANORMAL, INCLUIDO EL CANCER, EN UN MAMIFERO MEDIANTE LA ADMINISTRACION DE LOS COMPUESTOS DE FORMULA 1 AL MAMIFERO. LA INVENCION TAMBIEN SE REFIERE A LOS INTERMEDIOS Y METODOS UTILES PARA LA SINTESIS DE LOS COMPUESTOS DE FORMULA 1.
SV2000000020A 1999-02-11 2000-02-10 Derivados de quinolina-2-uno substituido de heteroarilo util como agente anti-canceroso ref.pc10198/82888/bb SV2001000020A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11970299P 1999-02-11 1999-02-11

Publications (1)

Publication Number Publication Date
SV2001000020A true SV2001000020A (es) 2001-11-08

Family

ID=22385869

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000020A SV2001000020A (es) 1999-02-11 2000-02-10 Derivados de quinolina-2-uno substituido de heteroarilo util como agente anti-canceroso ref.pc10198/82888/bb

Country Status (39)

Country Link
US (3) US6258824B1 (es)
EP (1) EP1150973B1 (es)
JP (3) JP4090200B2 (es)
KR (1) KR20010102073A (es)
CN (1) CN1340051A (es)
AP (1) AP2001002241A0 (es)
AR (1) AR028985A1 (es)
AT (1) ATE297916T1 (es)
AU (1) AU2124800A (es)
BG (1) BG105860A (es)
BR (1) BR0008202A (es)
CA (1) CA2362394C (es)
CO (1) CO5140097A1 (es)
CZ (1) CZ20012910A3 (es)
DE (1) DE60020812T2 (es)
DZ (1) DZ3009A1 (es)
EA (1) EA200100766A1 (es)
EE (1) EE200100425A (es)
ES (1) ES2243228T3 (es)
GT (1) GT200000014A (es)
HK (1) HK1042096A1 (es)
HN (1) HN2000000019A (es)
HR (1) HRP20010574A2 (es)
HU (1) HUP0105231A3 (es)
ID (1) ID29584A (es)
IL (1) IL144307A0 (es)
IS (1) IS5997A (es)
MA (1) MA26718A1 (es)
NO (1) NO20013909L (es)
OA (1) OA11833A (es)
PA (1) PA8490601A1 (es)
PE (1) PE20001464A1 (es)
PL (1) PL349839A1 (es)
SK (1) SK11002001A3 (es)
SV (1) SV2001000020A (es)
TN (1) TNSN00028A1 (es)
TR (2) TR200201297T2 (es)
WO (1) WO2000047574A1 (es)
ZA (1) ZA200106520B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2336624C (en) * 1998-07-06 2008-10-21 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
ID29584A (id) * 1999-02-11 2001-09-06 Pfizer Prod Inc Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker
ATE260269T1 (de) * 1999-11-05 2004-03-15 Cytovia Inc Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung
ES2212971T3 (es) * 1999-11-30 2004-08-16 Pfizer Products Inc. Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2001054688A1 (en) * 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1170011A1 (en) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Novel use of inhibitors of the epidermal growth factor receptor
JP4974438B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体
AU2001293826A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
WO2002024683A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
AU2001293835A1 (en) * 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
EA007464B1 (ru) * 2000-10-02 2006-10-27 Янссен Фармацевтика Н.В. Антагонисты метаботропных рецепторов глутамата
WO2002042296A1 (en) 2000-11-21 2002-05-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
EP1347966B1 (en) 2000-12-27 2006-03-08 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
DE60119383T2 (de) * 2000-12-27 2007-04-19 Janssen Pharmaceutica N.V. Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
WO2002092594A1 (en) * 2001-05-16 2002-11-21 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002092076A1 (en) * 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
CA2469275C (en) 2001-12-19 2011-09-06 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
ATE364384T1 (de) * 2002-03-22 2007-07-15 Janssen Pharmaceutica Nv Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
PL218788B1 (pl) * 2002-03-29 2015-01-30 Janssen Pharmaceutica Nv Znakowane radioaktywnie pochodne chinoliny i jej zastosowanie
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
EP1509515A4 (en) 2002-05-16 2006-07-05 Cytovia Inc SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H | CHROMENES AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE
AU2003241482A1 (en) 2002-05-16 2003-12-02 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
BR0317548A (pt) * 2002-12-19 2005-11-22 Pfizer Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
DK1603570T5 (da) 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
TW200504057A (en) * 2003-02-27 2005-02-01 Chugai Pharmaceutical Co Ltd Benzothiophene derivative
AU2004259755A1 (en) * 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
EP1691812A4 (en) 2003-11-20 2010-01-13 Childrens Hosp Medical Center GTPASE INHIBITORS AND METHOD OF USE
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
JP2007530654A (ja) * 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
MX2007001986A (es) * 2004-08-26 2007-05-10 Pfizer Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
JP4242911B2 (ja) 2004-08-26 2009-03-25 ファイザー・インク プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
CA2577937C (en) * 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2006041900A2 (en) * 2004-10-07 2006-04-20 Cytovia, Inc. SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS
US7826982B2 (en) 2005-07-29 2010-11-02 Children's Hospital Medical Center Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
DK1933871T3 (da) 2005-09-07 2013-07-08 Amgen Fremont Inc Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2009521470A (ja) * 2005-12-23 2009-06-04 リンク メディシン コーポレイション シヌクレイン障害の治療
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
MY150756A (en) 2006-08-21 2014-02-28 Hoffmann La Roche Tumor theraphy with an anti-vegf antibody
JP5492075B2 (ja) * 2007-05-23 2014-05-14 アラーガン インコーポレイテッド アドレナリンレセプター作用薬としての（（二環式ヘテロアリール）イミダゾリル）メチルヘテロアリール化合物
CA2688897A1 (en) * 2007-05-23 2008-11-23 Allergan, Inc. Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure
US8129356B2 (en) * 2007-10-01 2012-03-06 Vanderbilt University Bmx mediated signal transduction in irradiated vascular endothelium
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2010057006A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2393814A1 (en) 2009-02-09 2011-12-14 SuperGen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20110217309A1 (en) 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
PE20151203A1 (es) 2012-10-16 2015-08-31 Janssen Pharmaceutica Nv MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t
PE20150778A1 (es) 2012-10-16 2015-05-23 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de ror-gamma-t
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
DK2970205T3 (da) 2013-03-14 2019-07-29 Tolero Pharmaceuticals Inc JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9346782B2 (en) 2013-10-15 2016-05-24 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
CN108003150A (zh) * 2016-10-31 2018-05-08 河南工业大学 4-杂芳基喹啉酮衍生物的制备方法及其应用
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
EP4461315A3 (en) 2019-08-16 2025-03-05 Children's Hospital Medical Center Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732531A1 (de) * 1977-07-19 1979-02-01 Hoechst Ag Imidazolcarbonsaeuren und deren derivate
US4835154A (en) * 1987-06-01 1989-05-30 Smithkline Beckman Corporation 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
US5136085A (en) * 1990-11-28 1992-08-04 Glaxo Inc. Synthesis of 2-aminobenzophenones
US5053543A (en) * 1990-11-28 1991-10-01 Glaxo Inc. Synthesis of 2-aminobenzophenones
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EE03484B1 (et) * 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
DK0988038T3 (da) * 1997-06-02 2002-12-02 Janssen Pharmaceutica Nv Anvendelse af (imidazol-5-yl)methyl-2-quinolinon derivater til hæmning af glat muskelcelleproliferation
CA2341690C (en) 1998-08-27 2007-04-17 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
ID29584A (id) * 1999-02-11 2001-09-06 Pfizer Prod Inc Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker

Also Published As

Publication number Publication date
ES2243228T3 (es) 2005-12-01
BG105860A (en) 2002-03-29
SK11002001A3 (sk) 2002-05-09
WO2000047574A1 (en) 2000-08-17
CA2362394A1 (en) 2000-08-17
ID29584A (id) 2001-09-06
NO20013909L (no) 2001-10-08
GT200000014A (es) 2001-08-03
DE60020812D1 (de) 2005-07-21
TNSN00028A1 (fr) 2005-11-10
IL144307A0 (en) 2002-05-23
CN1340051A (zh) 2002-03-13
AR028985A1 (es) 2003-06-04
JP2005002124A (ja) 2005-01-06
DZ3009A1 (fr) 2004-03-27
JP2002536444A (ja) 2002-10-29
CA2362394C (en) 2006-01-17
PL349839A1 (en) 2002-09-23
TR200201297T2 (tr) 2002-06-21
PA8490601A1 (es) 2002-07-30
MA26718A1 (fr) 2004-12-20
TR200201296T2 (tr) 2002-07-22
HN2000000019A (es) 2001-07-30
EE200100425A (et) 2002-12-16
US6388092B2 (en) 2002-05-14
HUP0105231A2 (hu) 2002-04-29
IS5997A (is) 2001-07-10
EP1150973B1 (en) 2005-06-15
CZ20012910A3 (cs) 2002-02-13
JP4216740B2 (ja) 2009-01-28
CO5140097A1 (es) 2002-03-22
EP1150973A1 (en) 2001-11-07
JP2004182741A (ja) 2004-07-02
US6258824B1 (en) 2001-07-10
DE60020812T2 (de) 2006-05-04
BR0008202A (pt) 2002-02-19
AP2001002241A0 (en) 2001-09-30
HK1042096A1 (zh) 2002-08-02
EA200100766A1 (ru) 2002-02-28
NO20013909D0 (no) 2001-08-10
AU2124800A (en) 2000-08-29
KR20010102073A (ko) 2001-11-15
PE20001464A1 (es) 2000-12-20
US20020120145A1 (en) 2002-08-29
US6710209B2 (en) 2004-03-23
HRP20010574A2 (en) 2002-12-31
JP4090200B2 (ja) 2008-05-28
ATE297916T1 (de) 2005-07-15
HUP0105231A3 (en) 2003-01-28
OA11833A (en) 2005-08-23
ZA200106520B (en) 2002-08-26
US20020019530A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
SV2001000020A (es) Derivados de quinolina-2-uno substituido de heteroarilo util como agente anti-canceroso ref.pc10198/82888/bb
CU23413B7 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos
UY26143A1 (es) Derivados heterocíclicos útiles como agentes anticancerosos
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
CU23132A3 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PE20030257A1 (es) Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
SV1999000141A (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos ref. pc10411abcz/bb
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
AR018705A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos.
AR020032A1 (es) Derivados de 1,3 -metil eritromicina.
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
SV1999000252A (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer ref.pc10113abcz
TW200716528A (en) Cyclopropanecarboxamide derivatives
BR9805734A (pt) Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos.
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
TW200621694A (en) Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds
SV2004001419A (es) Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal" ref.pc23005
AR070949A1 (es) Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina
ECSP003347A (es) Derivados quinolin - 2- ona sustituidos con heteroarilo utiles como agentes anticancerigenos
AR044477A1 (es) Derivados de anilina, composiciones farmaceuticas que las contienen y procedimiento para su preparacion

Legal Events

Date Code Title Description
FD Lapse